Quick Dispatch:
Your case report aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists - Marroquin‐Harris - 2023 - Anaesthesia orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your case report aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists - Marroquin‐Harris - 2023 - Anaesthesia ships.
Need Help?
Questions about case report aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists - Marroquin‐Harris - 2023 - Anaesthesia, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for case report aspiration glp-1 receptor agonist anesthesia 2023 Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists - Marroquin‐Harris - 2023 - Anaesthesia in your area.
Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia
26.47
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice - Milder - 2024 - Anaesthesia
21.37
Glucagon-Like Peptide 1 Receptor Agonists and Aspiration Risk
29.28
Concerns have been raised about whether the delayed gastric emptying caused by GLP-1–based medications might jeopardize patient safety during procedures that require sedation. A randomized trial takes a closer look
25.75
🔸 Should GLP-1 RAs be continued preprocedurally? 🔸 Who should stop a GLP-1 RA preoperatively? 🔸 Which patients should have their procedures postponed? Read: https://doi.org/10.1097/01.ASM.0001125664.22893.9f
27.14
Managing patients taking glucagon-like peptide-1 receptor agonists: proceed with caution
26.01
Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system
22.88
